Gut Check: Current Trends in Microbiome Therapeutics Development

12:15 PM - 1:30 PM (PDT), Wednesday, June 15, 2022

As of March 31, 2022, reports 1,485 ongoing clinical studies related to the microbiome and targeting a myriad of disease indications, including autoimmune, gastrointestinal, infectious, metabolic and oncological disorders.  The therapeutic area's dramatic rise in clinical trial activity and positive results in 2021 illustrates the continuing progress and maturation of the field. With numerous mid-to-late-stage trials well underway, a host of 2022 readouts, and the first-ever microbiome therapy approval potentially on the cards, interest from big pharma and investors continues to grow and indicates that 2022 will be an explosive year for the microbiome field.  Join this panel of industry experts as they share recent gains in harnessing the power of the microbiome and what key stakeholders should be watching in the 2H of 2022 and beyond.

Sponsored By
Fujifilm Diosynth Biotechnologies
Chief Operating Officer
Vedanta Biosciences Inc
Executive Vice President, Chief Scientific Officer
Seres Therapeutics
VP Research
Finch Therapeutics Inc